Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients ...

Of the 17 picks we highlighted for 2025, only four are in the black for Q1, with one day left in the quarter. But it’s not a ...

Vera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this ...

Target 2x Long MSTR ETF offers even further leverage on MSTR, and therefore BTC. See why I rate MSTX fund a strong sell.

Analysts currently expect the company to post earnings of $2.27 per share on revenue of $2.12 billion for the quarter.

Cutting through the confusion is the 2025 AI Index from Stanford University’s Institute for Human-Centered Artificial ...

Today, we'll look at five stocks showing technical strength amidst this brutal correction. Using momentum indicators like ...

The charts clearly spell out a strong ... MW commitments made earlier this fiscal year. This stock has been experiencing some volatile trends in the last few weeks. The zig-zag moves seen in ...

What’s the secret for lasting chart success? A new report breaks down what gives hit songs their staying power ...

Gap Inc. stock offers value with a P/E below 10x, strong brand growth, a 3.5% dividend yield, and potential upside from trade ...

Based on a survey of 180 global asset owners, with investment portfolios ranging from US$1 billion to over US$500 billion, the findings highlight a growing focus on alternative investments, ...

DeFi hacks totaled $22 million in March, while macro-economic worries over Trump’s tariffs saw Bitcoin price slump.